Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues

Clinical and Translational Oncology

Volumn 11, Issue 1, 2009, Pages 48-53

  Muros, María Angustias ^a   Varsavsky, Mariela ^b   Iglesias Rozas, Pablo ^b   Valdivia, Javier ^b   Delgado, Juan Ramón ^a   Forrer, Flavio ^c   Bodei, Lisa ^d   Paganelli, Giovanni ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

177Lu DOTATATE; 90Y DOTATOC; Neuroendocrine tumours; Radiolabelled somatostatin analogues

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA INTERFERON; CARBOPLATIN; ETOPOSIDE; FLUOROURACIL; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LUTETIUM 177; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID YTTRIUM 90; SOMATOSTATIN DERIVATIVE; TEGAFUR; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; SOMATOSTATIN;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT FAILURE; TUMOR LOCALIZATION; CASE REPORT; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; QUALITY OF LIFE; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 65349111443     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-009-0310-5     Document Type: Article

References (23)

1. Clark O, Ajani JA, Kulke M et al (2005) Neuroendocrine tumors. In: National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology
2. Barakat MT, Meeran K, Bloom SR (2004) Neuroendocrine tumours. Endocr Relat Cancer 11:1-18
3. Valdes Olmos RA, Hoefnagel CA, Bais E et al (2001) Avances terapeúticos de medicina nuclear en Oncología. Rev Esp Med Nucl 20:547-557
4. Cremonesi M, Ferrari M, Zoboli S et al (1999) Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)YDOTATOC. Eur J Nucl Med 26:877-886
5. Waldherr C, Pless M, Maecke HR et al (2001) The clinical value of [90YDOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12:941-945
6. Waldherr C, Pless, M, Maecke HR et al (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90YDOTATOC. J Nucl Med 43:610-616
7. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754-2762
8. Paganelli G, Zoboli S, Cremonesi M et al (2001) Receptor-mediated radiotherapy with 90Y-DOTADPhe1-Tyr3-octreotide. Eur J Nucl Med 28:426-434
9. Bodei L, Cremonesi M, Grana C et al (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1038-1046
10. Valkema R, De Jong M, Bakker WH et al (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: The Rotterdam experience. Semin Nucl Med 32:110-122
11. Bodei L, Cremonesi M, Zoboli S et al (2003) Receptor-mediated radionuclide therapy with 90YDOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 30:207-216
12. Esser JP, Krenning EP, Teunissen JJ et al (2006) Comparison of [(177)Lu-DOTA (0),Tyr (3)]octreotate and [(177)Lu-DOTA (0),Tyr (3)]octreotide: Which peptide is preferable for PRRT? Eur J Nucl Med Molec Imaging 33:1346-1351
13. Reubi JC, Macke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46[Suppl 1]:67-75
14. Rolleman EJ, de Jong M, Valkema R et al (2006) Inhibition of kidney uptake of radiolabeled somatostatin analogues: Amino acids or gelofusine? J Nucl Med 47:1730-1731
15. Vegt E, Wetzels JF, Russel FG et al (2006) Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47:432-436
16. Behr TM, Behe M, Kluge G et al (2002) Nephrotoxicity versus anti-tumourefficacy in radiopeptide therapy: Facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging 29:277-279
17. Kwekkeboom DJ, Bakker WH, Kooij PP et al (2001) [177Lu-DOTA0Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 28:1319-1325
18. Kwekkeboom DJ, Bakker WH, Kam BL et al (2003) Treatment of patients with gastro-enteropancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate [abstract]. Eur J Nucl Med Mol Imaging 30:417-422
19. Kwekkeboom DJ, Bakker WH, Teunissen JJ et al (2003) Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results [abstract]. Eur J Nucl Med Mol Imaging 30[Suppl 2]:231
20. DeJong M, Valkema R, Jamar F et al (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32:133-140
21. Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46:62-66
22. Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130
23. Breeman WA, de Jong M, Kwekkeboom DJ et al (2001) Somatostatin receptor-mediated imaging and therapy: Basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28:1421-1429